TuHURA Biosciences, Inc. (HURA) News
Follow TuHURA Biosciences, Inc. (HURA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
TuHURA reports partial tumor remissions in first three patients
TuHURA reported partial tumor remissions in the first three patients in a study of IFx-2.0 with Keytruda.
EQUITY | Oct 26, 2026, 11:33 AM UTC
L
TuHURA Biosciences Receives New U.S. Patent for TBS-2025
The patent broadens coverage for the company’s VISTA inhibitor, TBS-2025.
EQUITY | Oct 13, 2026, 11:46 AM UTC
L
HURA - TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
HURA - TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 08, 2026, 11:45 AM UTC
L
TuHURA Biosciences reports second-quarter 2026 financial results
TuHURA Biosciences (HURA) reports second-quarter 2026 financial results and provides a corporate update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 11:45 AM UTC